Business
Frequency Therapeutics Announces Formation of Clinical Advisory Board for Remyelination in Multiple Sclerosis Program
Global Neurology Leaders to Support Development of a Potentially Restorative Treatment for MS as Program Advances Toward 2023 Regulatory Filing Company also
About this update from Korro Bio, Inc.
[{"type":"text","content":"\nGlobal Neurology Leaders to Support Development of a Potentially Restorative Treatment for MS as Program Advances Toward 2023 Regulatory Filing\n\nCompany also Expands Regenerative Medicine Advisory Board with Addition of Nobel Laureate and Cell Biologist Dr. James Rothman\n\n LEXINGTON, Mass.--(BUSINESS WIRE)--\nFrequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced that it has established a Clinical Advisory Board to help guide its remyelination in multiple sclerosis (MS) program. Comprised of leading experts from across the neurosciences, the Clinical Advisory Board will support clinical development and translation efforts as the Company advances its small molecule therapeutic candidate through human studies. The Company plans a regulatory filing for its remyelination program in the second half of 2023.\n\nThe Company also announced today that James Rothman, Ph.D., will join its Progenitor Cell Activation (PCA) Regenerative Medicine Advisory Board. Dr. Rothman is the Sterling Professor of Cell Biology at Yale University, Chairman of the Yale School of Medicine’s Department of Cell Biology and the Director and founder of the Nanobiology Institute. One of the world’s leading biochemists and cell biologists, he was awarded the Nobel Prize in Medicine in 2013 for his discovery of machinery regulating vesicle traffic, or the transfer of materials within cells, providing a framework to understand key physiological processes such as communication between nerve cells in the brain.\n\n“While a number of approved drugs are highly effective in preventing new inflammatory lesions, stopping gradual neurodegeneration and gradual clinical worsening remain the greatest areas of unmet need,” said Richard Rudick, Ph.D., the former Chief Clinical Research Officer at Cleveland Clinic, Vice Chairman for Research and Development in the Clinic’s Neurological Institute, and a member of Frequency’s Remyelination Clinical Advisory Board. “Supported by impressive preclinical data generated to date, Frequency has an opportunity to develop an entirely new therapy to address remyelination, and potentially provide those with MS with a first-in-class medicine with the hope of repairing damage caused by this c...